MétaCan
Menu
Back to cohort
Record W3182363921 · doi:10.1158/1538-7445.am2021-1313

Abstract 1313: TH1902, a docetaxel peptide-drug conjugate, shows pre-clinical efficacy in several Sortilin-positive (SORT1+) cancers

2021· article· en· W3182363921 on OpenAlexaff
Christian Marsolais, Jean-Christophe Currie, Michel Demeule, Cyndia Charfi, Alain Zgheib, Richard Béliveau, Borhane Annabi

Bibliographic record

VenueCancer Research · 2021
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicRNA Interference and Gene Delivery
Canadian institutionsUniversité du Québec à MontréalTheratechnologies (Canada)
Fundersnot available
KeywordsDocetaxelCancer researchInternalizationPharmacologyCytotoxic T cellMedicineIn vitroCancerIntracellularPancreatic cancerInternal medicineChemistryReceptorBiochemistry

Abstract

fetched live from OpenAlex

Abstract One strategy to achieve greater selectivity of anticancer drug to cancer cells is the conjugation of cytotoxic agents to peptide ligands that selectively target receptors abundantly expressed in these tumor cells. Recently, increased expression of sortilin (SORT1), a scavenging receptor, has been observed in various cancers including breast, ovarian, endometrial, skin, colorectal and pancreatic cancers. In light of these SORT1 levels, we developed a peptide conjugation platform to target SORT1 and to increase cell selectivity and internalization of anticancer agents. Docetaxel was conjugated to a sortilin-binding proprietary peptide (TH19P01). High in vitro intracellular internalization of TH19P01 in TNBC cells was first confirmed and was reduced when SORT1 expression was silenced using siRNA or upon competition with the SORT1 ligands neurotensin and progranulin. Significant in vitro intracellular delivery of the docetaxel-TH19P01 conjugate (TH1902) was observed in SORT1+ cancer cell lines while maintaining efficient docetaxel cytotoxic mechanism. TH1902 further exerted potent anti-proliferative and anti-migratory activities when tested on TNBC-derived MDA-MB-231 cells. TH1902 also triggered faster and more potent apoptotic cell death than did docetaxel. Pre-clinical in vivo studies were performed in human SORT1+ tumor xenografts grown in mice including TNBC (MDA-MB-231 and HCC-70), melanoma (SK-MEL-28), colorectal (HT-29) and pancreatic (PANC-1) cancer models. Mice were treated with either TH1902 or docetaxel by IV bolus injections at equivalent doses of docetaxel (MTD or ¼ MTD). In all cases, TH1902 showed more potent inhibition than Docetaxel. These results strongly support future clinical development of TH1902 as novel therapeutics in SORT1+ cancers. Citation Format: Christian Marsolais, Jean-Christophe Currie, Michel Demeule, Cyndia Charfi, Alain Larocque, Alain Zgheib, Richard Béliveau, Borhane Annabi. TH1902, a docetaxel peptide-drug conjugate, shows pre-clinical efficacy in several Sortilin-positive (SORT1+) cancers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 1313.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.003
Threshold uncertainty score0.010

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0030.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.066
GPT teacher head0.428
Teacher spread0.362 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2021
Admission routes1
Has abstractyes

Explore more

Same venueCancer ResearchSame topicRNA Interference and Gene DeliveryFrench-language works237,207